A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies  

作　　者：Lijun Zhao Shuhong Li Xiaoyi Wei Xuexiu Qi Qiaoru Guo Licai Shi Ji-Shuai Zhang Jun Li Ze-Lin Liu Zhi Guo Hongyu Zhang Jia Feng Yuanyuan Shi Suping Zhang Yu J.Cao 

机构地区：[1]State Key Laboratory of Chemical Oncogenomics,Shenzhen Key Laboratory of Chemical Genomics,Peking University Shenzhen Graduate School,Shenzhen 518055,China [2]The Shenzhen Pregene Biopharma Company,Ltd.,Shenzhen 518118,China [3]Fundamenta Therapeutics Co.,Ltd,Suzhou 215200,China [4]Department of Hematology,Huazhong University of Science and Technology Union Shenzhen Hospital,Nanshan Hospital,Shenzhen 518052,China [5]Department of Hematology,Peking University Shenzhen Hospital,Shenzhen 518036,China [6]Shenzhen Cell Valley Biomedical Co.,LTD,Shenzhen 518118,China [7]Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies,Base for International Science and Technology Cooperation:Carson Cancer Stem Cell Vaccines R&D Center,International Cancer Center,Shenzhen University Medical School,Shenzhen 518055,China [8]Institute of Chemical Biology,Shenzhen Bay Laboratory,Shenzhen 518132,China

出　　处：《Protein & Cell》2025年第3期227-232,共6页蛋白质与细胞(英文版)

基　　金：supported by the National Key R&D Program of China(2019YFA0906100 and 2019YFA0904200 to Y.J.C.);the Shenzhen Science and Technology Innovation Program(JCYJ20180504165501371 to Y.J.C.);the National Natural Science Foundation of China(32171464 and 81872783 to Y.J.C.),the Prevention and Control of COVID-2019 Research Program in University of Guangdong Province(2020KZDZX1176 to S.Z.);the Shenzhen Basic Research Program(JCYJ20180507182203049 to S.Z.);the Shenzhen Key Laboratory Foundation(ZDSYS20200811143757022 to S.Z.).

摘　　要：Dear Editor,Chimeric antigen receptor T(CAR-T)cells have achieved substantial advances in the treatment of B-cell malignancies.Despite high initial response rates,some patients relapse,characterized by targeted antigen loss(Shalabi et al.,2018).

关 键 词：B cell malignancies therapeutic efficacy targeted antigen loss shalabi bispecific CAR T cells CD 

分 类 号：R730.51[医药卫生—肿瘤]